Understand the source comparison
Best Research Peptides for Parkinson's Research: Mechanism Comparison
MOTS-c Mitochondrial biogenesis upregulation via PGC-1alpha activation Complex I function, ROS reduction Intranasal, intraperitoneal 5–15 mg/kg IP 3×/week Reduced ROS, improved mitochondrial respiration in aged brain tissue (USC study) Best for early-stage mit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- MOTS-c
- Mitochondrial biogenesis upregulation via PGC-1alpha activation
- Complex I function, ROS reduction
- Intranasal, intraperitoneal
- 5–15 mg/kg IP 3×/week
- Reduced ROS, improved mitochondrial respiration in aged brain tissue (USC study)
- Best for early-stage mitochondrial dysfunction modeling. Targets upstream pathology
- Semax
- BDNF and NGF upregulation, enkephalin modulation
- TrkB receptor activation, PI3K/Akt survival pathway
- 300–600 mcg intranasal daily or 50–100 mcg/kg IP
- 40% reduction in dopaminergic cell death in MPTP models (Journal of Molecular Neuroscience)
- Strongest evidence for synaptic maintenance and neurotrophin support
- Selank
- BDNF upregulation, GABAergic and serotonergic modulation
- Limbic dopaminergic circuits, anxiolytic pathways
- Intranasal
- 300–600 mcg intranasal daily
- Limited PD-specific data; anxiolytic effects documented in behavioral models
- Useful for non-motor symptom research (anxiety, depression) in PD models
- Cerebrolysin
- Multi-peptide neurotrophin mixture (BDNF-like, NGF-like, CNTF-like)
- Broad neuroprotection, excitotoxicity reduction
- Intravenous (clinical), intraperitoneal (preclinical)
- 30–60 mL IV in clinical trials; 2.5 mL/kg IP in rodents
- Mixed clinical trial results; modest motor and cognitive improvements as adjunct to levodopa
- Mechanistic ambiguity limits experimental control. Best as adjunct, not standalone